close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Newron Pharmaceuticals S.p.A.

News headline image
Newron Provides Update Following Type A Meeting With the FDA
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Pharmaceuticals to Participate in June Investor Conferences
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Presents 2025 Financial Results and Provides 2026 Outlook
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron presents H1 2025 results and provides business update
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Presents 2024 Financial Results and Provides 2025 Outlook
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron presents H1 2024 results and provides business update
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
From Newron Pharmaceuticals S.p.A.
Via Business Wire
News headline image
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today